Nu Skin Enterprises Inc. reports strong Q4 revenues, stock price increases by 9.8%.

From Zacks Investment Research: 2025-01-14 15:04:09

Shares of Nu Skin Enterprises Inc. (NUS) rose 9.8% as preliminary revenues for Q4 2024 hit the upper end of projections at $410-$445 million. Nu Skin’s subsidiary, Rhyz Inc., sold Mavely platform to Later for $250 million, generating capital for innovation and business growth. However, challenges persist in Nu Skin’s core business due to macroeconomic factors and direct selling industry pressures. NUS stock has dropped 33.4% in the past three months. Better-ranked picks include Abercrombie & Fitch Co. (ANF), The Gap Inc. (GAP) and Helen of Troy (HELE), each showing growth potential and positive earnings surprises.



Read more at Zacks Investment Research: NUS Q4 Preliminary Revenues Reach Top End of Outlook, Stock Gains 9.8% – January 14, 2025